This clinical trial is focused on studying Parkinson’s disease, specifically in its early stages. The treatment being tested is called prasinezumab, which is also known by its code name RO7046015. Prasinezumab is a type of medication that is given through an intravenous infusion, meaning it is administered directly into the bloodstream through a vein. The purpose of this study is to evaluate how effective prasinezumab is in treating early Parkinson’s disease over a period of 52 weeks.

Participants in the study will receive either prasinezumab or a placebo. The study is designed to be double-blind, which means neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The study will last for a total of 52 weeks, with an additional extension period where all participants will receive the treatment. During the study, participants will be monitored for changes in their symptoms and overall health.

Parkinson’s disease is a condition that affects movement, causing symptoms such as tremors, stiffness, and difficulty with balance and coordination. The study aims to see if prasinezumab can help improve these symptoms in people who are in the early stages of the disease. Participants will be assessed using various scales and tests to measure changes in their condition. The study will also monitor for any side effects or adverse reactions to the treatment. This research is important for understanding how prasinezumab might benefit people with early Parkinson’s disease and potentially improve their quality of life.